BioCentury
ARTICLE | Company News

NICE punts Tagrisso to Cancer Drugs Fund

October 3, 2016 7:00 AM UTC

The U.K.'s NICE issued a final appraisal determination recommending that Tagrisso osimertinib from AstraZeneca plc (NYSE:AZN; LSE:AZN) be covered by the Cancer Drugs Fund for locally advanced or metastatic T790M EGFR mutation-positive non-small cell lung cancer (NSCLC) that has progressed. The CDF coverage recommendation is NICE's first since the CDF was relaunched in July.

The European Commission granted conditional approval to Tagrisso for the indication in February. In draft guidance released in June, NICE recommended against Tagrisso because its long-term benefits were unclear and the drug could not be considered cost-effective. ...